Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Invega, paroxetine interaction data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Johnson & Johnson's schizophrenia therapy Invega (paliperidone) did not produce a drug-drug reaction when administered with the selective serotonin reuptake inhibitor paroxetine (GlaxoSmithKline's Paxil and generics), according to data presented at the American Psychiatric Association annual meeting in San Diego May 22. Sixty male patients were randomized to receive either paliperidone or paroxetine plus paliperidone. Four days after paliperidone administration, no clinically significant increases in paliperidone exposures were seen. "Drug interactions frequently occur in patients with schizophrenia because this population is often treated for multiple medical and psychiatric conditions," Johnson & Johnson Franchise Medical Leader for Psychiatry Joseph Palumbo said. Study results indicate that CYP2D6-inhibiting antidepressants can be administered with paliperidone, he said. Invega, a follow-on to J&J's Risperdal (risperidone), launched in January (1Pharmaceutical Approvals Monthly January 2007, In Brief)...

You may also be interested in...

J&J’s Invega to launch in January

Johnson & Johnson's antipsychotic Invega (paliperidone extended-release) received FDA approval Dec. 19, and the firm is set to launch the schizophrenia treatment in early January. The follow-on to Risperdal (risperidone) is the first new atypical antipsychotic approved by FDA for schizophrenia since 2003. Approval was based on three six-week, placebo-controlled trials in more than 1,600 patients worldwide. J&J is also conducting two Phase III head-to-head trials of Invega compared to AstraZeneca's Seroquel (quetiapine) in both schizophrenia and bipolar disorder; results are expected in 2007. Invega delivers paliperidone through the Alza OROS extended-release technology, which results in minimal fluctuations in blood level, according to J&J...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts